Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187910 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA14CA12KMT2AMEN1 | |
| SCHEMBL490446 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA14CA12KMT2AMEN1 | |
| SCHEMBL5606099 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12KMT2AMEN1 | |
| SCHEMBL8090761 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14CA12KMT2AMEN1 | |
| SCHEMBL11302194 | 0.81 | TSHR (0.35) | SMN1; SMN2KMT2AMEN1TSHR | |
| SCHEMBL2336327 | 0.80 | KMT2A (0.45) | SMN1; SMN2CA14CA12KMT2AMEN1 | |
| SCHEMBL8420441 | 0.80 | KMT2A (0.45) | SMN1; SMN2CA14CA12KMT2AMEN1 | |
| SCHEMBL2738378 | 0.80 | ALDH1A1 (0.39) | SMN1; SMN2 | |
| SCHEMBL4867613 | 0.79 | — | — | |
| SCHEMBL30415488 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | SMN1; SMN2 4657/4885CA14 4312/4885CA12 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.